# A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

Source: https://onco.cc/trials/nct07185880/  
OnCo record `nct07185880` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MT-125 in glioma & glioblastoma, run by Myosin Therapeutics Inc., now recruiting.

## Summary

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients is a phase 1/2 interventional study registered as NCT07185880 by Myosin Therapeutics Inc., with 36 participants planned, started 2026-04-01 and due to reach its primary completion in 2026-10-31. Interventions recorded: MT-125.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07185880
- Phase: 1/2
- Setting: A Phase 1/2 Single-Arm Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MT-125 Monotherapy With Radiation in Newly Diagnosed Glioblastoma
- Sponsor: Myosin Therapeutics Inc.
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07185880: https://clinicaltrials.gov/study/NCT07185880

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07185880.json